GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Instem PLC (LSE:INS) » Definitions » COGS-to-Revenue

Instem (LSE:INS) COGS-to-Revenue : 0.61 (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Instem COGS-to-Revenue?

Instem's Cost of Goods Sold for the six months ended in Jun. 2023 was £18.20 Mil. Its Revenue for the six months ended in Jun. 2023 was £29.74 Mil.

Instem's COGS to Revenue for the six months ended in Jun. 2023 was 0.61.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Instem's Gross Margin % for the six months ended in Jun. 2023 was 38.82%.


Instem COGS-to-Revenue Historical Data

The historical data trend for Instem's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instem COGS-to-Revenue Chart

Instem Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.44 0.59 0.57 0.56

Instem Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.55 0.53 0.58 0.61

Instem COGS-to-Revenue Calculation

Instem's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=33.06 / 58.88
=0.56

Instem's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=18.196 / 29.742
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instem  (LSE:INS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Instem's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 18.196 / 29.742
=38.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Instem COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Instem's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Instem (LSE:INS) Business Description

Traded in Other Exchanges
N/A
Address
Diamond Way, Stone Business Park, Stone, Staffordshire, GBR, ST15 0SD
Instem PLC acts as a supplier of IT applications and technology-enabled outsourced services to the global health and life sciences community. Its segments include Study Management, Regulatory Solutions, and In Silico Solutions, Clinical Trial Acceleration. The company generates maximum revenue from Study Management. Geographically, it derives a majority of its revenue from the United States and also has a presence in the Europe and Rest of the World. Its portfolio of software solutions includes Instem Cloud, SEND Data Conversion, KnowledgeScan, SENDReady Consulting, Solution Deployment, Validation, Data Management, and Regulatory Information Management.

Instem (LSE:INS) Headlines

No Headlines